


Posters and Abstracts with Cancer Trials Ireland Members involved presented at ESMO2018 Congress which this year attracted 28,000 attendees. (Follow hyperlinks for more detail.)

[Monitoring the effect of PI3K inhibition on HER2 therapy resistant breast cancer using serial analysis of PIK3CA mutant tumour DNA in plasma](#)

N. Keegan¹, S. Toomey², A. Farrelly², A. Carr², G. Calzaferri³, J. Walshe⁴, G. Gullo⁴, J.P. Crown⁴, K. Egan⁵, A. Hernando⁶, A. Teiserskiene⁶, L. Grogan⁷, O.S. Breathnach⁷, P.G. Morris⁵, B. Hennessy⁸

¹Department of Molecular Oncology, RCSI Beaumont Hospital, Dublin, Ireland, ²Oncology Molecular Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland, ³Department of Medical Oncology, Cancer Clinical Research Trust, Dublin, Ireland, ⁴Medical Oncology, St Vincent's University Hospital, Dublin, Ireland, ⁵Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland, ⁶Breast DSSG, Cancer Trials Ireland, Dublin, Ireland, ⁷Medical Oncology, Beaumont Hospital, Dublin, Ireland, ⁸Cancer Clinical Trials and Research Unit and Cancer Trials Ireland, RCSI Beaumont Hospital, Dublin, Ireland.



Pictured at the PanHER Poster at ESMO2018, Dr Sinead Toomey, lecturer and translational oncology research scientist at RCSI.

[The impact of the 21 gene recurrence score \(RS\) on chemotherapy \(CHemoRx\) prescribing in hormone receptor \(HR\) positive, lymph node positive \(LN1\) early-stage breast cancer \(BC\) in Ireland: A national, multi-centre, prospective study \(CTRIAL-IE 15-34\)](#)

Hassan¹, N. Keegan¹, C. O'Leary¹, L. McSorley¹, T. Mahgoub¹, S. O'Reilly², J. Walshe³, M.J. Kennedy⁴, L. Coate⁵, M. O'Connor⁶, M. Keane⁷, C.M. Kelly⁸, M. Milewski¹, S. Molloy¹, K. Egan¹, V. Murphy⁹, O.S. Breathnach¹, L. Grogan¹, B. Hennessy¹, P.G. Morris¹

¹Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland, ²Department of Medical Oncology, Cork University Hospital, Cork, Ireland, ³Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland, ⁴Oncology Directorate, St James's Hospital, Dublin, Ireland, ⁵Department of Medical Oncology, Mid-Western Cancer Centre, University Hospital Limerick, Dooradoyle, Ireland, ⁶Department of Medical Oncology, University Hospital Waterford, Waterford, Ireland, ⁷Department of Medical Oncology, University Hospital Galway, Galway, Ireland, ⁸Department of Medical Oncology, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland, ⁹Translational Research Unit, Cancer Trials Ireland, Dublin, Ireland.



Pictured at the 21 Recurrence Score poster at ESMO2018 018 were Dr Anees Hassan; the first author and consultant oncologist at Letterkenny University Hospital, Dr Verena Murphy; Translational Research Leader, Cancer Trials Ireland and Dr Kathleen Scott; Head of Operations and Clinical Programs, Cancer Trials Ireland.

[Clinical outcomes in patients \(pts\) with estrogen receptor-positive \(ER1\)/human epidermal growth factor receptor 2-negative \(HER2-\) advanced breast cancer \(ABC\) with objective response \(OR\) or without objective response \(non-OR\) in PALOMA-2](#)

H.S. Rugo¹, R.S. Finn², K.A. Gelmon³, A.A. Joy⁴, O.N. Lipatov⁵, N. Harbeck⁶, A. Castellon⁷, H. Mukai⁸, J.M. Walshe⁹, A. Mori¹⁰, E. Gauthier¹¹, D.R. Lu¹², E. Bananis¹³, M. Martin¹⁴, V. Dieras¹⁵

¹Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA, ²Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA, ³Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada, ⁴Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada, ⁵Department of Oncology, Republican Clinical Oncology Dispensary, Ufa, Russian Federation, ⁶Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany, ⁷Breast Cancer Center, Memorial Healthcare System, Pembroke Pines, FL, USA, ⁸Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan, ⁹Medical Oncology Department, Cancer Trials Ireland, Dublin, Ireland, ¹⁰Global Product Development, Clinical, Pfizer S.r.l., Milan, Italy, ¹¹Global Product Development, Clinical, Pfizer Inc., San Francisco, CA, USA, ¹²Global Product Development, Statistics, Pfizer Inc., La Jolla, CA, USA, ¹³US Medical Affairs, Pfizer Oncology, New York, NY, USA, ¹⁴Universidad Complutense, Hospital Gregorio Marañon, Madrid, Spain, ¹⁵Department of Medical Oncology, Centre Eugene Marquis and Institut Curie, Rennes, France.

[Non-invasive genotyping and monitoring of tumor evolution in locally advanced rectal cancer \(LARC\) patients using circulating tumor DNA \(ctDNA\)](#)

S. Toomey¹, A. Sartori², D. Irwin³, S. Hummel⁴, A. Carr¹, C.L. Lee⁵, P. Armstrong¹, A. Farrelly⁶, S. El-Masry⁷, D. McNamara⁸, P.G. Morris⁹, L. Grogan⁹, O.S. Breathnach⁹, L. O'Sullivan¹⁰, S. Bradshaw¹¹, A.N.A.M. Rashed¹², R. Smyth¹, J. Workman¹, B. O'Neill¹³, B. Hennessy⁹

¹Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland, ²Scientific Affairs, Agena Biosciences, Hamburg, Germany, ³Agena Bioscience, Brisbane, Australia, ⁴Agena Bioscience, San Diego, CA, USA, ⁵Medical Oncology, St Vincents University Hospital, Dublin, Ireland, ⁶Oncology Molecular Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland, ⁷Surgery, Our Lady of Lourdes Hospital, Drogheda, Ireland, ⁸Surgery, Beaumont Hospital, Dublin, Ireland, ⁹Medical Oncology, Beaumont Hospital, Dublin, Ireland, ¹⁰Cancer Trials Ireland, Dublin, Ireland, ¹¹Radiation Oncology, St Luke's Radiation Oncology Network, Dublin, Ireland, ¹²Oncology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland, ¹³Radiation Oncology, St. Luke's Radiation Oncology Network, Dublin, Ireland

[Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial](#)

A. Curioni¹, E. Felip², U. Dafni³, M-A. Molina⁴, O. Gautschi⁵, S. Peters⁶, B. Massuti⁷, R. Palmero⁸, S. Ponce⁹, E. Carcereny¹⁰, M. Fruh¹¹, M. Pless¹², S. Popat¹³, S. Cuffe¹⁴, N. Karachaliou¹⁵, R. Kammler¹⁶, M. Kassapian¹⁷, H. Roschitzki-Voser¹⁶, R.A. Stahel¹, R. Rosell¹⁵

¹Department of Haematology and Oncology, Division of Oncology, University Hospital Zurich, Zurich, Switzerland, ²Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain, ³National and Kapodistrian University of Athens and, Frontier Science Foundation-Hellas, Athens, Attica, Greece, ⁴Pangaea Biotech S.L., Quiron Dexeus University Hospital, Barcelona, Spain, ⁵Medical Oncology, Cantonal Hospital Lucerne, Lucern, Switzerland, ⁶De'partement d'Oncologie, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, Switzerland, ⁷ISABIAL Oncologia Me'dica, Hospital Universitario Alicante, Alicante, Spain, ⁸Catalan Institute of Oncology, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Llobregat, Spain, ⁹Oncologia Medica, Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹⁰Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Badalona, Spain, ¹¹Swiss Group for Clinical Cancer Research (SAKK) and Department of Oncology / Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ¹²Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland, ¹³Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, UK, ¹⁴Cancer Trials Ireland and Medical Oncology, St James's Hospital, Dublin, Ireland, ¹⁵Institute of Oncology Rosell, University Hospital Sagrat Cor, Barcelona, Spain, ¹⁶European Thoracic Oncology Platform (ETOP), Bern, Switzerland, ¹⁷National and Kapodistrian University of Athens, Frontier Science Foundation-Hellas, Athens, Greece.

[Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma \(EOC\) treatment](#)

A.R. Clamp¹, I.A. McNeish², A. Dean³, D. Gallardo-Rincon⁴, J-W. Kim⁵, D.M. O'Donnell⁶, J. Hook⁷, S. Blagden⁸, J.D. Brenton⁹, R. Naik¹⁰, T.J. Perren⁷, S. Sundar¹¹, A.D. Cook¹², E.C. James¹³, H. Gabra¹⁴, R. Lord¹⁵, M. Hall¹⁶, G. Dark¹⁷, R.S. Kaplan¹³, J.A. Ledermann¹⁸

¹Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK, ²Department of Surgery and Cancer, Imperial College London, London, UK, ³Medical Oncology, Saint John of God Hospital Subiaco, Subiaco, Australia, ⁴Gynecology Oncology Clinic, Instituto Nacional de Cancerologia - Mexico, Ciudad De Me'xico, Mexico, ⁵Gynecologic Oncology, KGOG & Seoul National University, Seoul, Republic of Korea, ⁶Medical Oncology, Cancer Trials Ireland, Dublin, Ireland, ⁷Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, ⁸Oncology, Churchill Hospital University of Oxford, Oxford, UK, ⁹Li Ka Shing Centre, Cancer Research UK, Cambridge Research Institute Addenbrooke's Hospital, Cambridge, UK, ¹⁰Northern Gynaecological Oncology Centre, Gateshead Health NHS Foundation Trust, Gateshead, UK, ¹¹Birmingham Gynaecological Cancer Centre, University of Birmingham, Birmingham, UK, ¹²MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology-UCL, London, UK, ¹³MRC, Institute of Clinical Trials and Methodology-UCL, London, UK, ¹⁴Surgery and Cancer, Imperial College London -Hammersmith Hospital, London, UK, ¹⁵Clatterbridge Cancer Centre, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK, ¹⁶Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK, ¹⁷Northern Cancer for Cancer Care, Newcastle University, Newcastle, UK, ¹⁸Cancer Trials Centre, University College London Cancer Institute, London, UK.

[A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial](#)

S. Peters¹, S.J. Danson², B. Hasan³, N. Reinmuth⁴, M. Majem⁵, K.G. Tournoy⁶, M.T. Mark⁷, M. Pless⁸, M. Cobo⁹, D. Rodriguez-Abreu¹⁰, L. Falchero¹¹, B. Massuti¹², L. Coate¹³, R. von Moos¹⁴, C.C. Zielinski¹⁵, E. De Maio³, M. O'Brien¹⁶, H. Roschitzki-Voser¹⁷, U. Dafni¹⁸, R.A. Stahel¹⁹

¹Departement d'Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, ²University of Sheffield, Weston Park Hospital, Sheffield, UK, ³European Organisation for Research and Treatment of Cancer (EORTC), Headquarters, Brussels, Belgium, ⁴Asklepios Kliniken GmbH, Asklepios Fachkliniken Muenchen-Gauting, Gauting, Germany, ⁵Medical Oncology Department, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain, ⁶Onze-Lieve-Vrouw Ziekenhuis (OLV) Aalst and, Faculty of Medicine and Life Sciences, Ghent University, Ghent, Belgium, ⁷Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland, ⁸Medical Oncology and Hematology, Kantonsspital Winterthur, Winterthur, Switzerland, ⁹Oncologia Medica, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ¹⁰Servicio Oncologia Medica, Hospital Insular De Gran Canaria, Las Palmas, Spain, ¹¹Medical Oncology, Hopital Nord-Ouest Villefranche, Gleize, France, ¹²Spanish Lung Cancer Group (SLCG) and, Hospital Universitario Alicante - ISABIAL Oncologia Medica, Alicante, Spain, ¹³Cancer Trials Ireland, University Hospital Limerick, Limerick, Ireland, ¹⁴Swiss Group for Clinical Cancer Research (SAKK) and, Kantonsspital Graubunden, Chur, Switzerland, ¹⁵Central European Cooperative Oncology Group (CECOG), Comprehensive Cancer Center, Medical University, Vienna, Austria, ¹⁶Medical Oncology, Royal Marsden Hospital, Sutton, UK, ¹⁷European Thoracic Oncology Platform (ETOP), Coordinating Office, Bern, Switzerland, ¹⁸Frontier Science Foundation-Hellas and, National and Kapodistrian University of Athens, Athens, Greece, ¹⁹Department of Haematology and Oncology, Division of Oncology, University Hospital Zurich, Zurich, Switzerland.